Contrasting LENSAR (LNSR) and The Competition

LENSAR (NASDAQ:LNSR – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare LENSAR to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.

Profitability

This table compares LENSAR and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LENSAR 56.07% 1,254.25% 49.13%
LENSAR Competitors -303.57% -175.14% -22.20%

Analyst Ratings

This is a summary of current ratings and price targets for LENSAR and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR 1 0 2 0 2.33
LENSAR Competitors 4291 10580 18364 831 2.46

LENSAR presently has a consensus price target of $11.00, indicating a potential upside of 134.04%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.40%. Given LENSAR’s higher possible upside, analysts clearly believe LENSAR is more favorable than its peers.

Institutional and Insider Ownership

40.1% of LENSAR shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares LENSAR and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
LENSAR $58.44 million -$34.28 million -11.75
LENSAR Competitors $1.87 billion $136.27 million 5.88

LENSAR’s peers have higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

LENSAR has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, LENSAR’s peers have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Summary

LENSAR peers beat LENSAR on 7 of the 13 factors compared.

About LENSAR

(Get Free Report)

LENSAR, Inc. is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation. Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.

Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.